Abstract
The etiology of coronary spastic angina (CSA) remains uncertain. Mice lacking the gene encoding the inwardly rectifying K(+) channel Kir6.1 were developed as an animal model of CSA. We investigated whether mutation in the coding region of the Kir6.1 gene is detected in Japanese patients with CSA. The study population included 19 Japanese patients with CSA (10 men and 9 women with a mean age of 61+/-14 years). Mutational analysis of the coding region of Kir6.1 was performed by direct sequencing. We found no missense or nonsense mutations in these samples, but we found in one female CSA patient, a single base substitution (C to T) at nucleotide position 111 in exon 2 of the coding region, which was heterozygous and did not cause amino acid substitution (Ile37Ile, silent mutation). In the remaining 18 patients, no base substitution was detected in the coding region of the Kir6.1 gene. No mutation that alters primary structure of Kir6.1 was detected in Japanese patients with CSA. The results indicate that abnormality in the primary structure of Kir6.1 may not be involved in the genetic pathogenesis of CSA in humans.
Introduction
Coronary spastic angina (CSA) is characterized by sudden constriction of the coronary arteries, which can lead to myocardial infarction or sudden cardiac death. While the condition is more prevalent in Japanese populations compared to Caucasian populations, the underlying genetic mechanisms remain poorly understood.
Animal models have provided significant clues. Specifically, mice lacking the gene for Kir6.1—a critical component of the ATP-sensitive potassium (K<sub>ATP</sub>) channel in vascular smooth muscle—exhibit symptoms identical to human CSA. Given this strong phenotypic link, researchers hypothesized that mutations in the human Kir6.1 gene might be a primary driver of CSA, particularly in high-risk Japanese cohorts.
Methods
The study analyzed 19 Japanese patients (10 men, 9 women; mean age 61±14 years) diagnosed with CSA via coronary arteriography. Genomic DNA was extracted from whole blood samples for mutational analysis.
The researchers targeted the coding regions of the Kir6.1 gene, specifically exons 2 and 3. As shown in the schematic above, three specific primer sets (F1, F2, and F3) were used for Polymerase Chain Reaction (PCR) amplification. The resulting products were analyzed via direct sequencing on an ABI Prism 310 genetic analyzer and compared against the NCBI reference sequence (NM_004982).
Results
The analysis revealed a high degree of sequence conservation across the patient cohort. In 18 of the 19 patients, the coding region of the Kir6.1 gene was identical to the reference sequence. No missense (amino acid-altering) or nonsense (truncating) mutations were identified.
Only one genetic variant was detected: a single female patient exhibited a heterozygous base substitution (C to T) at nucleotide position 111 in exon 2. As illustrated in the chromatograms above, this change corresponds to a "silent mutation" (Ile37Ile), meaning it does not alter the primary amino acid sequence of the protein and therefore has no functional impact on the channel's structure.
Discussion
These findings highlight a notable translational gap between mouse models and human pathology. While Kir6.1 deficiency causes CSA in mice, the primary structure of the channel appears stable in human patients. This suggests that the genetic roots of CSA in humans likely lie outside the Kir6.1 coding sequence.
The researchers propose that the dysfunction may instead involve regulatory subunits of the K<sub>ATP</sub> complex, such as SUR2B. Alternatively, the channel might be functionally inhibited by external signaling pathways. Previous studies have noted enhanced Phospholipase C (PLC)-δ1 activity in CSA patients, which is known to inhibit K<sub>ATP</sub> channels. Thus, the channel may be structurally sound but functionally "silenced" by secondary signaling interference.
Conclusion and Future Directions
This study concludes that abnormalities in the primary structure of Kir6.1 are likely not involved in the genetic pathogenesis of CSA in Japanese patients. However, the small sample size (n=19) remains a limitation, potentially missing rare variants.
Future research should expand to include:
- Regulatory Subunits: Sequencing the SUR2B gene to identify potential defects in channel regulation.
- Non-Coding Regions: Investigating promoter regions or introns that might affect gene expression levels.
- Large-Scale GWAS: Utilizing larger cohorts to identify broader genetic associations beyond the K<sub>ATP</sub> channel complex.
Summary updated